Completed PHASE2/PHASE3 INTERVENTIONAL 3-arm NCT03723655

A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM

A Long-Term Safety Extension Study of Mavacamten (MYK-461) in Adults With Hypertrophic Cardiomyopathy Who Have Completed the MAVERICK-HCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE)

Sponsor: Bristol-Myers Squibb

Conditions Hypertrophic Cardiomyopathy Non-obstructive Hypertrophic Cardiomyopathy Obstructive Hypertrophic Cardiomyopathy

Interventions mavacamten

Updated 27 times since 2018 Last updated: Feb 18, 2026 Started: Sep 27, 2018 Primary completion: Jan 16, 2026 Completion: Jan 16, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Hypertrophic Cardiomyopathy and Non-obstructive Hypertrophic Cardiomyopathy, this trial is completed. The trial is conducted by Bristol-Myers Squibb and has accumulated 27 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

27 versions recorded

Feb 2026 — Present [monthly]

Completed PHASE2/PHASE3

Status: Active Not Recruiting → Completed
Sep 2025 — Feb 2026 [monthly]

Active Not Recruiting PHASE2/PHASE3
Jul 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE2/PHASE3
Oct 2024 — Jul 2025 [monthly]

Active Not Recruiting PHASE2/PHASE3
Sep 2024 — Oct 2024 [monthly]

Active Not Recruiting PHASE2/PHASE3

▶ Show 22 earlier versions

Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Apr 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE2_PHASE3
Apr 2023 — Apr 2024 [monthly]

Active Not Recruiting PHASE2_PHASE3
Sep 2022 — Apr 2023 [monthly]

Active Not Recruiting PHASE2_PHASE3

Status: Enrolling By Invitation → Active Not Recruiting
Jul 2022 — Sep 2022 [monthly]

Enrolling By Invitation PHASE2_PHASE3
Jun 2022 — Jul 2022 [monthly]

Enrolling By Invitation PHASE2_PHASE3
Oct 2021 — Jun 2022 [monthly]

Enrolling By Invitation PHASE2_PHASE3
Sep 2021 — Oct 2021 [monthly]

Enrolling By Invitation PHASE2_PHASE3
May 2021 — Sep 2021 [monthly]

Enrolling By Invitation PHASE2_PHASE3
Jan 2021 — May 2021 [monthly]

Enrolling By Invitation PHASE2_PHASE3
Dec 2020 — Jan 2021 [monthly]

Enrolling By Invitation PHASE2_PHASE3
Sep 2020 — Dec 2020 [monthly]

Enrolling By Invitation PHASE2_PHASE3
Aug 2020 — Sep 2020 [monthly]

Enrolling By Invitation PHASE2_PHASE3
May 2020 — Aug 2020 [monthly]

Enrolling By Invitation PHASE2_PHASE3
Feb 2020 — May 2020 [monthly]

Enrolling By Invitation PHASE2_PHASE3
Dec 2019 — Feb 2020 [monthly]

Enrolling By Invitation PHASE2_PHASE3
Oct 2019 — Dec 2019 [monthly]

Enrolling By Invitation PHASE2_PHASE3
Sep 2019 — Oct 2019 [monthly]

Enrolling By Invitation PHASE2_PHASE3
Aug 2019 — Sep 2019 [monthly]

Enrolling By Invitation PHASE2_PHASE3
Jul 2019 — Aug 2019 [monthly]

Enrolling By Invitation PHASE2_PHASE3
Dec 2018 — Jul 2019 [monthly]

Enrolling By Invitation PHASE2_PHASE3
Nov 2018 — Dec 2018 [monthly]

Enrolling By Invitation PHASE2_PHASE3

First recorded

Sep 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb

Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Aalst, Belgium , Aarhus, Denmark , Almada, Portugal , Ann Arbor, United States , Bad Nauheim, Germany , Bethlehem, United States , Boston, United States , Brussels, Belgium , Charlotte, United States and 54 more locations